Association of SLCO1B3 Polymorphism with Intracellular Accumulation of Imatinib in Leukocytes in Patients with Chronic Myeloid Leukemia

Access this Article

Search this Article

Author(s)

    • Nambu Takeru Nambu Takeru
    • Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University
    • Hamada Akinobu Hamada Akinobu
    • Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University|Department of Pharmacy, Kumamoto University Hospital
    • Yuki Misato
    • Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University
    • Kawaguchi Tatsuya
    • Department of Hematology and Infectious Diseases, Kumamoto University Hospital
    • Mitsuya Hiroaki
    • Department of Hematology and Infectious Diseases, Kumamoto University Hospital
    • Saito Hideyuki
    • Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University|Department of Pharmacy, Kumamoto University Hospital

Abstract

Intracellular concentration of imatinib in leukemic cells is thought to affect the clinical efficacy of this drug in patients with chronic myeloid leukemia (CML); however, there is no report that directly indicates the relationship between intracellular concentration and clinical outcome and/or, plasma concentration. In addition, the impacts of genetic variations of drug transporters, which mediate leukocyte concentration of imatinib, are unknown. In the present study, we investigated the correlation between intracellular imatinib concentrations in leukocytes, plasma imatinib levels, and genotypes of drug transporters, including <i>ATP binding cassette B1</i> (<i>ABCB</i>), <i>ABCG2</i>, <i>solute carrier 22A1</i> (<i>SLC22A1</i>), <i>solute carrier organic anion transporter family members 1B1</i> (<i>SLCO1B1</i>) and <i>SLCO1B3</i>. The imatinib levels in leukocytes were determined using HPLC in 15 patients with chronic phase CML. No significant correlation between intracellular and plasma concentrations of imatinib was observed. The intracellular concentration was comparable in both patients with or without complete cytogenetic response. The intracellular imatinib concentration was significantly higher in patients with <i>SLCO1B3</i> 334TT than in those with 334TG/GG (<i>p</i>=0.0188). Plasma concentrations were similar in both <i>SLCO1B3</i> genotypes (<i>p</i>=0.860), thereby resulting in the intracellular to plasma concentration ratio being higher in patients with <i>SLCO1B3</i> 334TT than those with 334 TG/GG (<i>p</i>=0.0502). These results suggested that the <i>SLCO1B3</i> 334T>G polymorphism could have a significant impact on the intracellular concentration of imatinib in leukocytes as a promising biomarker for personalized treatment of CML patients.

Journal

  • Biological and Pharmaceutical Bulletin

    Biological and Pharmaceutical Bulletin 34(1), 114-119, 2011

    The Pharmaceutical Society of Japan

Codes

  • NII Article ID (NAID)
    130000402273
  • NII NACSIS-CAT ID (NCID)
    AA10885497
  • Text Lang
    ENG
  • ISSN
    0918-6158
  • NDL Article ID
    10926911
  • NDL Source Classification
    ZS51(科学技術--薬学)
  • NDL Call No.
    Z53-V41
  • Data Source
    NDL  J-STAGE 
Page Top